

in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iv.iiarjournals.org

Selection of Recent Articles

Cryopreservation of Viable Human Lung Tissue for Versatile Post-thaw Analyses and Culture. J.E. BAATZ, D.A. NEWTON, E.C. RIEMER, C.E. DENLINGER, E.E. JONES, R.R. DRAKE, D.D. SPYROPOULOS (*Charleston, SC, USA*)

Establishment and Characterization of New Orthotopic and Metastatic Neuroblastoma Models. E. DAUDIGEOS-DUBUS, L. LE DRET, V. ROUFFIAC, O. BAWA, I. LEGUERNEY, P. OPOLON, G. VASSAL, B. GEOERGER (*Orsay; Villejuif, France*)

Comparative Study of Prescribing Patterns of Tigecycline for Trial-Patients versus Non-Trial-Patients. J.J. HORSCHT, J.B. ZIMMERMANN, M.A. WEIGAND, T. BRUCKNER, E.O. MARTIN, T. HOPPE-TICHY, S. SWOBODA (*Heidelberg; Gießen, Germany*)

Effects of the Bifunctional Sulfoxide MMS350, A Radiation Mitigator, on Hematopoiesis in Long-Term Bone Marrow Cultures and on Radioresistance of Marrow Stromal Cell Lines. A. SHINDE, M.W. EPPERLY, S. CAO, D. FRANICOLA, D. SHIELDS, H. WANG, P. WIPF, M.M. SPRACHMAN, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

The Need for Surgery in Acute Abdominal Pain: A Randomized Study of Abdominal Computed Tomography. P. JUVONEN, T. LEHTIMÄKI, M. ESKELINEN, I. ILVES, R. VANNINEN, P. MIETTINEN, H. PAAJANEN (*Kuopio, Finland*)

Inhibitory Action of Levocetirizine on the Production of Eosinophil Chemoattractants RANTES and Eotaxin In Vitro and In Vivo. A. KANEI, K. ASANO, K.-I. KANAI, A. FURUTA, K. SASAKI, H. SUZAKI (*Tokyo; Yokohama, Japan*)

Poor Memory Performance in Aged Cynomolgus Monkeys with Hippocampal Atrophy, Depletion of Amyloid Beta 1-42 and Accumulation of Tau Proteins in Cerebrospinal Fluid. H.S. DARUSMAN, J. PANDELAKI, R. MULYADI, D. SAJUTHI, I.A. PUTRI, O.H. KALLIOKOSKI, J. CALL, K.S.P. ABELSON, S.J. SCHAPIRO, A. GJEDDE, J. HAU (*Copenhagen; Aarhus, Denmark; Jakarta; Bogor, Indonesia; Leipzig, Germany; Bastrop, TX; Baltimore, MD, USA; Montreal, QC, Canada*)

Effects of Interactions between Progesterone and Prostaglandin on Uterine Contractility in Perfused Swine Uterus Model. J. KÜNZEL, K. GEISLER, T. MALTARIS, A. MÜLLER, I. HOFFMANN, H. SCHNEIDER, M.W. BECKMANN, R. DITTRICH, P.G. OPPELT (*Erlangen, Germany*)

Esophageal Radioprotection in Thoracic Irradiated Mice with Transgenic Lung Tumors by Swallowed JP4-039/F15. M.W. EPPERLY, J.P. GOFF, D. FRANICOLA, H. WANG, P. WIPF, S. LI, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. E. SMOLLE, V. TAUCHER, J. HAYBAECK (*Graz, Austria*)

Increased DNA Integrity in Colorectal Cancer. G. LESZINSKI, J. LEHNER, U. GEZER, S. HOLDENRIEDER (*Munich; Bonn, Germany; Istanbul, Turkey*)

Circulating Human Fractalkine is Decreased Post-operatively After Orthopedic and Coronary Bypass Surgery. T. EKERFELDT, J. HELMERSSON-KARLQVIST, T. GORDH, A. LARSSON (*Uppsala, Sweden*)

Circulating miR-18a; A Sensitive Cancer Screening Biomarker in Human Cancer. S. KOMATSU, D. ICHIKAWA, H. TAKESHITA, R. MORIMURA, S. HIRAJIMA, M. TSUJIURA, T. KAWAGUCHI, M. MIYAMAE, H. NAGATA, H. KONISHI, A. SHIOZAKI, E. OTSUJI (*Kyoto, Japan*)

Antioxidant Effects of Lipophilic Tea Polyphenols on Diethylnitrosamine/Phenobarbital-induced Hepatocarcinogenesis in Rats. F. ZHOU, T. SHEN, T. DUAN, Y.-Y. XU, S.C. KHOR, Y.-F. ZHENG, S. HSU, J. DE STEFANO, J. YANG, L.-H. XU, X.-Q. ZHU (*Hangzhou, Zhejiang; Shanghai, PR China; Augusta, GA, USA*)

Anti-inflammatory Effects of Polihexanide and Polyethylene glycol in an In-vitro Study in Chronic Rhinosinusitis. R. BIRK, J. GROSSBAIER, C. ADERHOLD, J. STERN-STRÄTER, K. HÖRMANN, A. SAUTER, J.U. SOMMER (*Heidelberg, Germany*)

Anti-UV Activity of Kampo Medicines and Constituent Plant Extracts: Re-evaluation with Skin Keratinocyte System. T. KATO, S. HINO, N. HORIE, T. SHIMOYAMA, T. KANEKO, K. KUSAMA, H. SAKAGAMI (*Saitama; Tokyo, Japan*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

Instructions to Authors 2014

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios
 International Institute of Anticancer Research (IIAR)
 Editorial Office of ANTICANCER RESEARCH,
 IN VIVO, CANCER GENOMICS and PROTEOMICS.
 1st km Kapandritiou-Kalamou Road
 P.O. Box 22, GR-19014 Kapandriti, Attiki
 GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Relationship Between <i>EGFR</i> Mutations and Clinicopathological Features of Lung Adenocarcinomas Diagnosed via Small Biopsies. H.J. KIM, E.Y. CHOI, H.J. JIN, K.-C. SHIN (<i>Daegu, Republic of Korea</i>)	3189
The Role of Sentinel Lymph Node Biopsy in Patients with Local Recurrence or In-Transit Metastasis of Melanoma. M. GIPPONI, N. SOLARI, D. GIOVINAZZO, P. QUEIROLO, S. BERTOGLIO, G. VILLA, M. GUALCO, D. BLEIDL, F. CAFIERO (<i>Genoa, Italy</i>)	3197
Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib. O. FIALA, M. PESEK, J. FINEK, L. BENESOVA, M. MINARIK, Z. BORTLICEK, O. TOPOLCAN (<i>Prague; Brno, Czech Republic</i>)	3205
Microsatellite Instability Analysis in Uterine Cavity Washings to Detect Endometrial Cancer in Lynch Syndrome. A.-S. BATS, H. BLONS, C. NARJOZ, M.-A. LE FRERE-BELDA, P. LAURENT-PUIG, F. LECURU (<i>Paris, France</i>)	3211
<i>NAT2</i> , <i>XRCC1</i> and <i>hOGG1</i> Polymorphisms, Cigarette Smoking, Alcohol Consumption and Risk of Upper Aerodigestive Tract Cancer. C.R. MARQUES, T.M. DA SILVA, D.M. DE ALBUQUERQUE, M.S. CHAVES, M.F. MARQUES FILHO, J.S. OLIVEIRA, G. DI PIETRO, S.M.B. SOUSA, A.L. SIMÕES, F. RIOS-SANTOS (<i>Ilhéus; Jequié; Campinas; Lagarto; Vitória da Conquista; Ribeirão Preto; Cuiabá, Brazil</i>)	3217
Impact of Preoperative Thrombocytosis on Pathological Outcomes and Survival in Patients Treated with Radical Cystectomy for Bladder Carcinoma. M. MOSCHINI, N. SUARDI, F. PELLUCCHI, L. ROCCHINI, G. LA CROCE, U. CAPITANIO, A. BRIGANTI, R. DAMIANO, F. MONTORSI, R. COLOMBO (<i>Milan; Reggio Emilia; Catanzaro, Italy</i>)	3225
Errata	3231
Book Reviews	3233
Announcements	3241

Synovial Sarcoma in Knee Joint, Mimicking Low-grade Sarcoma Confirmed by Molecular Detection of <i>SYT</i> Gene Split. H. KIMURA, N. YAMAMOTO, H. NISHIDA, K. HAYASHI, A. TAKEUCHI, T. NOJIMA, H. IKEDA, S. SAWADA-KITAMURA, H. TSUCHIYA (<i>Kanazawa, Ishikawa, Japan</i>)	3105
Intratumoral But Not Peritumoral Lymphatic Vessel Density Measured by D2-40 Expression Predicts Poor Outcome in Gastric Cancer – ROC Curve Analysis to Find Cut-off Point. P. DONIZY, J. RUDNO-RUDZINSKA, A. HALON, M. DZIEGALA, J. KABAROWSKI, E. FREJLICH, P. DZIEGIEL, W. KIELAN, R. MATKOWSKI (<i>Wroclaw, Poland</i>)	3113
Histological Changes After Radiation Therapy in Patients with Lung Cancer: A Prospective Study. G. KARPATHIU, A. GIATROMANOLAKI, M.I. KOUKOURAKIS, V. MIHAILIDIS, E. SIVRIDIS, D. BOUROS, M.E. FROUDARAKIS (<i>Alexandroupolis, Greece</i>).....	3119
Gemcitabine-based Adjuvant Chemotherapy for Patients with Advanced Gallbladder Cancer M. NAKAMURA, H. NAKASHIMA, T. ABE, T. ENSAKO, K. YOSHIDA, K. HINO (<i>Kurashiki, Japan</i>)	3125
Glasgow Prognostic Score Is a Useful Predictive Factor of Outcome After Palliative Gastrectomy for Stage IV Gastric Cancer. K. MIMATSU, T. OIDA, N. FUKINO, H. KANO, A. KAWASAKI, K. KIDA, Y. KUBOI, S. AMANO (<i>Kanagawa; Tokyo, Japan</i>)	3131
Prognostic Significance of Pre- and Postoperative Glasgow Prognostic Score for Patients with Non-small Cell Lung Cancer. M. TOMITA, T. AYABE, E. CHOSA, K. NAKAMURA (<i>Kiyotake, Miyazaki, Japan</i>)	3137
Effect of Long Interval Between Hyperthermochemoradiation Therapy and Surgery for Rectal Cancer on Apoptosis, Proliferation and Tumor Response. T. KATO, T. FUJII, M. IDE, T. TAKADA, T. SUTOH, H. MORITA, R. YAJIMA, S. YAMAGUCHI, S. TSUTSUMI, T. ASAO, T. OYAMA, H. KUWANO (<i>Maebashi, Gunma; Mibu, Tochigi, Japan</i>)	3141
Vascular Invasion, but not Lymphatic Invasion, of the Primary Tumor Is a Strong Prognostic Factor in Patients with Colorectal Cancer. T. FUJII, T. SUTOH, H. MORITA, R. YAJIMA, S. YAMAGUCHI, S. TSUTSUMI, T. ASAO, H. KUWANO (<i>Maebashi, Gunma; Mibu, Tochigi, Japan</i>).....	3147
Excellent Prognosis of Lepidic-predominant Lung Adenocarcinoma: Low Incidence of Lymphatic Vessel Invasion as a Key Factor. K. ARAKI, Y. KIDOKORO, K. HOSOYA, M. WAKAHARA, Y. MATSUOKA, Y. TAKAGI, T. HARUKI, K. MIWA, Y. TANIGUCHI, S. HORIE, H. NAKAMURA (<i>Yonago, Japan</i>)	3153
Histological Growth Pattern of and Alpha-actinin-4 Expression in Thyroid Cancer. N. TANAKA, T. YAMASHITA, S. YAMAMOTO, T. MATSUNOBU, H. TSUDA, K. HONDA, T. YAMADA, S. TAMAI, A. SHIOTANI (<i>Saitama; Tokyo, Japan</i>).....	3157
Utility of Measuring Circulating Tumor Cell Counts to Assess the Efficacy of Treatment for Carcinomas of Unknown Primary Origin. K. KOMINE, M. INOUE, K. OTSUKA, K. FUKUDA, H. NANJO, H. SHIBATA (<i>Akita, Japan</i>)	3165
Short-term Clinical Outcomes of Postoperative Intrapelvic Bleeding After Extended Pelvic Surgery: A Single Institute Experience. H. OGAWA, T. MIZUSHIMA, I. TAKEMASA, H. YAMAMOTO, Y. DOKI, M. MORI (<i>Suita, Osaka, Japan</i>)	3169
Hypothyroidism as a Predictive Clinical Marker of Better Treatment Response to Sunitinib Therapy. D. KUST, M. PRPIĆ, J. MURGIĆ, M. JAZVIĆ, B. JAKŠIĆ, D. KRILIĆ, A. BOLANČA, Z. KUSIĆ (<i>Zagreb, Croatia</i>)	3177
Gefitinib and Afatinib Treatment in an Advanced Non-small Cell Lung Cancer (NSCLC) Patient Undergoing Hemodialysis. M. BERSANELLI, M. TISEO, F. ARTIOLI, L. LUCCHI, A. ARDIZZONI (<i>Parma; Modena, Italy</i>).....	3185

Insulin-like Growth Factor Receptor 1 mRNA Expression as a Prognostic Marker in Advanced Non-small Cell Lung Cancer. A. VILMAR, E. SANTONI-RUGIU, J. GARCIA-FONCILLAS, M. HUARRIZ, J.B. SØRENSEN (<i>Copenhagen, Denmark; Pamplona, Spain</i>)	2991
Preliminary Clinical Outcomes of Image-guided 3-Dimensional Conformal Radiotherapy for Limited Brain Metastases Instead of Stereotactic Irradiation Referral. K. OHTAKARA, H. HOSHI (<i>Gifu; Seki, Gifu, Japan</i>) ...	2997
An Additional Case of Gastric Serrated Adenoma. C.A. RUBIO, P.T. SCHMIDT (<i>Stockholm, Sweden</i>)	3007
Survival and Prognostic Factors in Pancreatic and Ampullary Cancer. J. LEMKE, D. SCHÄFER, S. SANDER, D. HENNE-BRUNS, M. KORNMANN (<i>Ulm, Germany</i>)	3011
NF1 Truncating Mutations Associated to Aggressive Clinical Phenotype with Elephantiasis Neuromatosa and Solid Malignancies. G. PONTI, D. MARTORANA, G. PELLACANI, C. RUINI, P. LOSCHI, A. BACCARANI, G. DE SANTIS, A. POLLIO, T.M. NERI, V.D. MANDEL, A. MAIORANA, L. MACCIO, M. MACCAFERRI, A. TOMASI (<i>Modena; Parma; Padova, Italy</i>)	3021
<i>XRCC1</i> rs25487 Polymorphism Predicts the Survival of Patients After Postoperative Radiotherapy and Adjuvant Chemotherapy for Breast Cancer. M. TENGSTRÖM, A. MANNERMAA, V.-M. KOSMA, A. HIRVONEN, V. KATAJA (<i>Kuopio; Helsinki, Finland</i>)	3031
Clinical Efficacy of Non-transplant Therapies in Patients with Hepatocellular Carcinoma with Child-Pugh C Liver Cirrhosis. H. NISHIKAWA, R. KITA, T. KIMURA, Y. OHARA, H. TAKEDA, A. SAKAMOTO, S. SAITO, N. NISHIJIMA, A. NASU, H. KOMEKADO, Y. OSAKI (<i>Osaka-Sayama, Osaka, Japan</i>)	3039
Clinical Trial of a 7-Peptide Cocktail Vaccine with Oral Chemotherapy for Patients with Metastatic Colorectal Cancer. K. OKUNO, F. SUGIURA, K. INOUE, Y. SUKEGAWA (<i>Osaka, Japan</i>)	3045
Prognostic Significance of Urine N ¹ ,N ¹² -Diacylspermine in Patients with Non-small Cell Lung Cancer. M. KATO, H. ONISHI, K. MATSUMOTO, J. MOTOSHITA, N. TSURUTA, K. HIGUCHI, M. KATANO (<i>Fukuoka, Japan</i>)	3053
Cell-Adhesion Molecule Expression and the Proliferation of Malignant Mesothelioma: A Post-Mortem Examination. K. KURIBAYASHI, H. HIRANO, K. NAKASHO, H. OHYAMA, K. YAMANEGI, C. TABATA, K. FUKUOKA, Y. FUJIMORI, T. NAKANO (<i>Gifu; Osaka; Hyogo, Japan</i>)	3061
Long-term Follow-up of Intermediate-risk Non-muscle Invasive Bladder Cancer Sub-classified by Multi-coloured FISH. C. MIAN, E. COMPLOJ, E. RESNYAK, E. TRENTI, S. PALERMO, M. LODDE, A. PYCHA, A. AMBROSINI-SPALTRO, C.B. DECHET, A. PYCHA (<i>Bolzano, Italy; Riga, Latvia; Salt Lake City, UT, USA</i>)	3067
Atypical Lipomatous Tumor with Structural Rearrangements Involving Chromosomes 3 and 8. J. NISHIO, H. IWASAKI, K. NABESHIMA, Y. KAMACHI, M. NAITO (<i>Fukuoka, Japan</i>)	3073
Role of Novel Risk Classification Method, Prostate Cancer Risk Index (PRIX) for Clinically Localized Prostate Cancer After Highdose- rate Interstitial Brachytherapy as Monotherapy. K. YOSHIDA, H. YAMAZAKI, S. NAKAMURA, K. MASUI, T. KOTSUMA, H. AKIYAMA, E. TANAKA, Y. YOSHIOKA (<i>Takatsuki; Suita, Osaka; Kyoto, Japan</i>)	3077
Detection of Circulating Tumor Cells in Colorectal and Gastric Cancer Using a Multiplex PCR Assay. A.G. VAIPOULOS, I.D. KOSTAKIS, E. GKIOKA, K.C. ATHANASOULA, E. PIKOULIS, A. PAPALAMBROS, P. CHRISTOPOULOS, H. GOGAS, G. KOURAKLIS, M. KOUTSILIERIS (<i>Athens, Greece</i>)	3083
How to Improve the Outcome in Patients with AJCC Stage I Hepatocellular Carcinoma. A.Q. YAP, C.A. MILLAN, J.-H. WANG, C.-C. WANG, S.-N. LU, S.-H. WANG, C.-C. LIN, Y.-W. LIU, C.-C. YONG, W.-F. LI, T.-L. LIN, C.-L. CHEN (<i>Kaohsiung, Taiwan, ROC</i>)	3093

Induction of Caspase-dependent Apoptosis by Apigenin by Inhibiting STAT3 Signaling in HER2-overexpressing MDA-MB-453 Breast Cancer Cells. H.-S. SEO, J.M. KU, H.-S. CHOI, J.-K. WOO, B.-H. JANG, Y.C. SHIN, S.-G. KO (<i>Seoul; Incheon, Republic of Korea</i>)	2869
Effects of Targeting Endometrial Stromal Sarcoma Cells <i>via</i> Histone Deacetylase and PI3K/AKT/mTOR Signaling. P. QUAN, F. MOINFAR, I. KUFFERATH, M. ABSSENGER, T. KUEZNIK, H. DENK, K. ZATLOUKAL, J. HAYBAECK (<i>Graz; Linz, Austria</i>)	2883
Preconditioning with Hyperbaric Oxygen in Pancreaticoduodenectomy: a Randomized Double-blind Pilot Study. G. BOSCO, A. CASAROTTO, E. NASOLE, E. CAMPORESI, R. SALVIA, F. GIOVINAZZO, S. ZANINI, G. MALLEO, A. DI TANO, A. RUBINI, V. ZANON, D. MANGAR, C. BASSI (<i>Padova; Verona, Italy; Tampa, FL, USA</i>).....	2899
Cell-cycle Distribution and Thymidilate Synthase (TS) Expression Correlate with 5-FU Resistance in Head and Neck Carcinoma Cells. K. IJICHI, M. ADACHI, T. OGAWA, Y. HASEGAWA, S. MURAKAMI (<i>Nagoya; Nagakute, Aichi; Gifu, Japan</i>)	2907
Effect of EPH-Ephrin Signaling on the Growth of Human Leukemia Cells. Y. TAKAHASHI, M. ITOH, N. NARA, S. TOHDA (<i>Tokyo, Japan</i>)	2913
PPM1D as a Novel Biomarker for Prostate Cancer After Radical Prostatectomy. L. JIAO, D. SHEN, G. LIU, J. JIA, J. GENG, H. WANG, Y. SUN (<i>Shanghai; Changchun, Jilin, PR China</i>).....	2919
RAD001 Enhances the Radiosensitivity of SCC4 Oral Cancer Cells by Inducing Cell Cycle Arrest at the G ₂ /M Checkpoint. C.-C. YU, S.-K. HUNG, H.-F. LIAO, C.-C. LEE, H.-Y. LIN, H.-C. LAI, S.-C. LI, H.-C. HO, H.-B. HUANG, Y.-C. SU (<i>Chia-Yi; Hualian; Taipei, Taiwan, ROC</i>)	2927
Pattern of Somatostatin Receptors Expression in Normal and Bladder Cancer Tissue Samples. M. KARAVITAKIS, P. MSAOUEL, V. MICHALOPOULOS, M. KOUTSILIERIS (<i>Athens, Greece; Bronx, NY, USA</i>).....	2937
Genetic Polymorphism of <i>miR-196a</i> as a Prognostic Biomarker for Early Breast Cancer. S.J. LEE, J.W. SEO, Y.S. CHAE, J.G. KIM, B.W. KANG, W.W. KIM, J.H. JUNG, H.Y. PARK, J.Y. JEONG, J.-Y. PARK (<i>Daegu, Republic of Korea</i>)	2943
Contribution of DNA Double-strand Break Repair Gene <i>XRCC3</i> Genotypes to Oral Cancer Susceptibility in Taiwan. C.-W. TSAI, W.-S. CHANG, J.-C. LIU, M.-H. TSAI, C.-C. LIN, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	2951
Hyperoxia Resensitizes Chemoresistant Glioblastoma Cells to Temozolomide Through Unfolded Protein Response. D. LEE, S. SUN, A.S.W. HO, K.M.Y. KIANG, X.Q. ZHANG, F.F. XU, G.K.K. LEUNG (<i>Pokfulam, Hong Kong</i>)	2957
The Steroidal Na ⁺ /K ⁺ ATPase Inhibitor 3-[(R)-3-Pyrrolidinyl]oxime Derivative (3-R-POD) Induces Potent Pro-Apoptotic Responses in Colonic Tumor Cells. S.H. ALKAHTANI (<i>Riyadh, Saudi Arabia</i>)	2967
FIP-gts Potentiate Autophagic Cell Death Against Cisplatin-resistant Urothelial Cancer Cells. J.-R. LI, C.-L. CHENG, W.-J. YANG, C.-R. YANG, Y.-C. OU, M.-J. WU, J.-L. KO (<i>Taichung, Taiwan, ROC</i>).....	2973
<i>Clinical Studies</i>	
DNA Methylation in Paired Breast Epithelial and White Blood Cells from Women Undergoing Reduction Mammoplasty. S.R. STURGEON, K.F. ARCARO, M.A. JOHNSON, R. BALASUBRAMANIAN, M. ZORN, D.J. JERRY, S. SMITH SCHNEIDER (<i>Amherst; Springfield, MA, USA</i>).....	2985

Collaborative Network of Predictive Markers Complicates Formation of Prognostic Groups in Patients with Advanced Lung Cancer. B. SCHWAB, A. RUDOLPH, E. JOST, U. KLINGE (<i>Aachen; Neubiberg, Germany</i>) ...	2745
Immunohistochemical Comparison of Biomarker Expression in Biopsy and Surgical Specimens of Non-small Cell Lung Cancer. T. OKIMOTO, Y. TSUBATA, A. SUTANI, H. FUCHITA, N. KOBA, T. HOTTA, M. HAMAGUCHI, K. MIURA, S. HAMAGUCHI, M. OHE, T. KURAKI, Y. HARADA, R. MARUYAMA, N. MIYAMOTO, K. KISHIMOTO, T. ISOBE (<i>Shimane, Japan</i>)	2755
Diallyl Disulfide Inhibits TNF α -induced CCL2 Release by MDA-MB-231 Cells. D. BAUER, E. MAZZIO, K.F. SOLIMAN, E. TAKA, E. ORIAKU, T. WOMBLE, S. DARLING-REED (<i>Tallahassee, FL, USA</i>)	2763
The Role of Type D Prostanoid Receptors and PPAR γ in Gastric Cancer Progression. T. FUKUOKA, M. YASHIRO, T. MORISAKI, H. KINOSHITA, T. HASEGAWA, H. KASASHIMA, G. MASUDA, K. SAKURAI, T. TOYOKAWA, H. TANAKA, N. KUBO, K. MUGURUMA, M. OHIRA, K. HIRAKAWA (<i>Osaka, Japan</i>) ...	2771
Identification of Metabolic Signatures Associated with Erlotinib Resistance of Non-small Cell Lung Cancer Cells. M. SERIZAWA, M. KUSUHARA, V. ZANGIACOMI, K. URAKAMI, M. WATANABE, T. TAKAHASHI, K. YAMAGUCHI, N. YAMAMOTO, Y. KOH (<i>Shizuoka; Wakayama, Japan</i>).....	2779
Cell-Cycle Analysis and Apoptosis-associated Proteins in Cervical Lesions of Brazilian Women. C. DOBO, C.T. OSHIMA, F. DE OLIVEIRA LIMA, T.S. GOMES, J.N. STÁVALE, V. ARIAS, D.A. RIBEIRO, G.R.A. FOCCHI (<i>São Paulo, SP, Brazil</i>)	2789
Heparanase and COX-2 Expression as Predictors of Lymph Node Metastasis in Large, High-grade Breast Tumors. S. GAWTHORPE, J.E. BROWN, M. ARIF, P. NIGHTINGALE, A. NEVILL, A.R. CARMICHAEL (<i>Birmingham; Walsall; Dudley, UK</i>)	2797
Predicting the Sensitivity to Ion Therapy Based on the Response to Photon Irradiation – Experimental Evidence and Mathematical Modelling. C. MOHANTY, K. ZIELINSKA-CHOMEJ, M. EDGREN, R. HIRAYAMA, T. MURAKAMI, B. LIND, I. TOMA-DASU (<i>Stockholm, Sweden; Chiba, Japan</i>)	2801
Development of a Dihydroartemisinin-resistant Molt-4 Leukemia Cell Line. J. PARK, H.C. LAI, M. SINGH, T. SASAKI, N.P. SINGH (<i>Seattle, WA, USA</i>)	2807
Influence of Hypoxia Inducible Factors on the Immune Microenvironment in Ovarian Cancer. M. DUECHLER, L. PECZEK, M. SZUBERT, J. SUZIN (<i>Lodz, Poland</i>)	2811
SOD3 Acts as a Tumor Suppressor in PC-3 Prostate Cancer Cells via Hydrogen Peroxide Accumulation. J. KIM, A. MIZOKAMI, M. SHIN, K. IZUMI, H. KONAKA, Y. KADONO, Y. KITAGAWA, E.T. KELLER, J. ZHANG, M. NAMIKI (<i>Kanazawa, Ishikawa, Japan; Ann Arbor, MI, USA; Nanning, Guangxi, China</i>)	2821
HSPA2 Is Expressed in Human Tumors and Correlates with Clinical Features in Non-small Cell Lung Carcinoma Patients. D. SCIEGLINSKA, A. GOGLER-PIGLOWSKA, D. BUTKIEWICZ, M. CHEKAN, E. MALUSECKA, J. HARASIM, A. HABRYKA, Z. KRAWCZYK (<i>Gliwice; Zabrze, Poland</i>)	2833
Primary and Secondary Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. J. SIMASI, A. SCHUBERT, C. OELKRUG, A. GILLISSEN, K. NIEBER (<i>Leipzig; Kassel, Germany</i>)	2841
The Role of Claudin-1 and Claudin-7 in Cervical Tumorigenesis. C. CUNNIFFE, B. BRANKIN, H. LAMBKIN, F. RYAN (<i>Dublin, Ireland</i>)	2851
Spontaneous In Vitro Senescence of Glioma Cells Confirmed by an Antibody Against IDH1 ^{R132H} . E. STOCZYNSKA-FIDELUS, W. OCH, P. RIESKE, M. BIENKOWSKI, M. BANASZCZYK, M. WINIECKA-KLIMEK, J. ZIEBA, K. JANIK, K. ROSIAK, C. TREDI, R. STAWSKI, A. RADOMIAK-ZALUSKA, S. PIASKOWSKI (<i>Lodz; Olsztyn; Zgierz, Poland</i>)	2859